rethinkTHC Search
Menu
Study breakdown

A CB1 neutral antagonist blocked fentanyl effects in rats without the side effects of rimonabant

Animal StudyPreliminary evidence
The takeaway

The CB1 neutral antagonist AM4113 blocked fentanyl discrimination in rats at lower doses and without the response-suppressing side effects seen with rimonabant, supporting its potential as a novel opioid use disorder treatment.

Addiction pharmacologists, opioid use disorder researchers, and drug development scientists.

AM4113 blocked fentanyl effects at 10x lower doses than those affecting food intake

What the researchers found

AM4113 (0.32-1.0 mg/kg) effectively blocked fentanyl discrimination at doses that did not reduce food-maintained responding. Rimonabant (1.0-10 mg/kg) only partially attenuated fentanyl effects at the highest dose, which also significantly decreased response rates. Mu-opioid agonists fully substituted for fentanyl, confirming opioid mediation.

Why it matters

Current opioid use disorder treatments are limited. A CB1 neutral antagonist that blocks fentanyl effects without the psychiatric side effects that ended rimonabant could offer a new therapeutic approach.

The numbers in context

AM4113 effective doses: 0.32-1.0 mg/kg. Rimonabant partial effect only at 10 mg/kg (with rate suppression). AM4113 was effective at 10-fold lower doses than those affecting food responding.

How the study worked

Male rats trained to discriminate 0.032 mg/kg fentanyl from saline under a fixed-ratio 10 schedule of food reinforcement. Tested effects of CB1 neutral antagonist AM4113 and inverse agonist rimonabant on fentanyl discrimination and food-maintained responding.

What this study cannot tell us

Animal study in rats. Drug discrimination assay measures subjective effects, not addiction-related behaviors. Only male rats tested. Translation to human opioid use disorder uncertain.

How to read the evidence

Well-designed animal pharmacology study with appropriate controls, but requires human translation.

When this study was published

Published in 2022.

The bigger picture

The functional interaction between cannabinoid and opioid systems opens a novel therapeutic avenue for the opioid crisis, particularly since CB1 neutral antagonists may avoid the depression and anxiety that doomed rimonabant.

Questions still open

  • Would AM4113 also block the reinforcing properties of fentanyl in self-administration models? Could CB1 neutral antagonists be used alongside existing opioid treatments?

Common questions

Could cannabinoid drugs help treat opioid addiction?
In rats, a CB1 neutral antagonist (AM4113) effectively blocked fentanyl's subjective effects without the side effects that ended the previous CB1 drug rimonabant, suggesting a promising new approach.
What is a neutral antagonist?
Unlike inverse agonists like rimonabant that push receptor activity below baseline (causing depression and anxiety), neutral antagonists simply block the receptor without shifting its baseline activity.

Read the original research

Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.

Drug and alcohol dependence, 240, 109646

Citation

AlKhelb, Dalal; Kirunda, Andre; Ho, Thanh C; Makriyannis, Alexandros; Desai, Rajeev I. (2022). Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.. Drug and alcohol dependence, 240, 109646. https://doi.org/10.1016/j.drugalcdep.2022.109646

Explore the wider topic